UNLABELLED: Systemic infections with Candida albicans in neonates are a frequent and well recognized problem. The therapeutic gold standard in this situation is the combined intravenous antimycotic treatment with amphotericin B and flucytosine. Potential adverse effects of this regimen have encouraged the search for desirable alternatives. We report on the use of oral fluconazole in neonates with Candida albicans septicaemia. Three premature infants were treated with four courses of therapy. Pharmacokinetic studies were performed during each course. At oral doses of 4.5-6 mg/kg once a day, serum levels of fluconazole were within the therapeutic range during the entire dosage interval. Follow up showed microbiological and clinical cure in all patients with no side-effects. In one patient a dosage of 4 mg/kg per day lead to a microbiological relapse with sub-therapeutic serum levels. CONCLUSIONS: Oral fluconazole seems to be a safe and effective treatment for Candida albicans septicaemia even in premature infants.
UNLABELLED: Systemic infections with Candida albicans in neonates are a frequent and well recognized problem. The therapeutic gold standard in this situation is the combined intravenous antimycotic treatment with amphotericin B and flucytosine. Potential adverse effects of this regimen have encouraged the search for desirable alternatives. We report on the use of oral fluconazole in neonates with Candida albicans septicaemia. Three premature infants were treated with four courses of therapy. Pharmacokinetic studies were performed during each course. At oral doses of 4.5-6 mg/kg once a day, serum levels of fluconazole were within the therapeutic range during the entire dosage interval. Follow up showed microbiological and clinical cure in all patients with no side-effects. In one patient a dosage of 4 mg/kg per day lead to a microbiological relapse with sub-therapeutic serum levels. CONCLUSIONS: Oral fluconazole seems to be a safe and effective treatment for Candida albicans septicaemia even in premature infants.
Authors: K C Wade; D Wu; D A Kaufman; R M Ward; D K Benjamin; J E Sullivan; N Ramey; B Jayaraman; K Hoppu; P C Adamson; M R Gastonguay; J S Barrett Journal: Antimicrob Agents Chemother Date: 2008-09-22 Impact factor: 5.191
Authors: Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2014-07 Impact factor: 6.447
Authors: Jeremiah D Momper; Edmund V Capparelli; Kelly C Wade; Anand Kantak; Ramasubbareddy Dhanireddy; James J Cummings; Jonathan H Nedrelow; Mark L Hudak; Gratias T Mundakel; Girija Natarajan; Jamie Gao; Matt Laughon; P Brian Smith; Daniel K Benjamin Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.938
Authors: Michael F Hwang; Ryan J Beechinor; Kelly C Wade; Daniel K Benjamin; P Brian Smith; Christoph P Hornik; Edmund V Capparelli; Shahnaz Duara; Kathleen A Kennedy; Michael Cohen-Wolkowiez; Daniel Gonzalez Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.938